Solid Accounts Payable vs Common Stock Total Equity Analysis

SLDB Stock

USD 6.03 0.08 1.31%

Solid Biosciences financial indicator trend analysis is much more than just breaking down Solid Biosciences LLC prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Solid Biosciences LLC is a good investment. Please check the relationship between Solid Biosciences Accounts Payable and its Common Stock Total Equity accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Solid Biosciences LLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in consumer price index.

Accounts Payable vs Common Stock Total Equity

Accounts Payable vs Common Stock Total Equity Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Solid Biosciences LLC Accounts Payable account and Common Stock Total Equity. At this time, the significance of the direction appears to have weak relationship.

The correlation between Solid Biosciences' Accounts Payable and Common Stock Total Equity is 0.31. Overlapping area represents the amount of variation of Accounts Payable that can explain the historical movement of Common Stock Total Equity in the same time period over historical financial statements of Solid Biosciences LLC, assuming nothing else is changed. The correlation between historical values of Solid Biosciences' Accounts Payable and Common Stock Total Equity is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Accounts Payable of Solid Biosciences LLC are associated (or correlated) with its Common Stock Total Equity. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Common Stock Total Equity has no effect on the direction of Accounts Payable i.e., Solid Biosciences' Accounts Payable and Common Stock Total Equity go up and down completely randomly.

Correlation Coefficient

0.31

Relationship Direction	Positive
Relationship Strength	Very Weak

View All Relationships

Accounts Payable

An accounting item on the balance sheet that represents Solid Biosciences obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Solid Biosciences LLC are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.

Common Stock Total Equity

The total value of common stock equity held by shareholders, representing their ownership interest in the company.

Most indicators from Solid Biosciences' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Solid Biosciences LLC current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Solid Biosciences LLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in consumer price index.

As of August 19, 2025, Selling General Administrative is expected to decline to about 22.4 M. In addition to that, Issuance Of Capital Stock is expected to decline to about 82.9 M

	2022	2023	2024	2025 (projected)
Depreciation And Amortization	2.4M	2.6M	2.5M	2.1M
Interest Income	2.6M	7.0M	9.5M	9.9M

Depreciation And Amortization Interest Income

Solid Biosciences fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Net Debt	Retained Earnings	Accounts Payable	Cash	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Short Term Investments	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Preferred Stock Total Equity	Total Current Assets	Common Stock	Property Plant And Equipment Net	Current Deferred Revenue	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Deferred Long Term Liab
Total Assets		0.13	0.77	0.97	0.92	-0.83	-0.83	0.49	0.91	0.99	-0.16	0.49	0.65	-0.69	0.9	0.93	-0.62	0.79	0.99	-0.16	0.81	0.85	0.82	-0.14	0.19	0.8
Other Current Liab	0.13		0.33	-0.01	0.19	0.16	-0.29	-0.45	-0.03	0.13	-0.21	0.58	0.39	0.06	0.06	0.09	0.11	-0.24	0.12	-0.21	0.14	-0.13	0.14	-0.16	-0.41	-0.08
Total Current Liabilities	0.77	0.33		0.74	0.75	-0.66	-0.75	0.38	0.73	0.77	-0.25	0.57	0.46	-0.62	0.67	0.79	-0.49	0.6	0.77	-0.25	0.6	0.73	0.61	-0.24	0.21	0.61
Total Stockholder Equity	0.97	-0.01	0.74		0.94	-0.84	-0.82	0.57	0.91	0.96	-0.23	0.45	0.57	-0.82	0.92	0.94	-0.76	0.84	0.96	-0.23	0.8	0.94	0.8	-0.2	0.19	0.84
Net Tangible Assets	0.92	0.19	0.75	0.94		-0.67	-0.95	0.55	0.81	0.89	-0.23	0.73	0.59	-0.76	0.92	0.96	-0.71	0.79	0.89	-0.23	0.84	0.9	0.85	-0.18	0.05	0.87
Net Debt	-0.83	0.16	-0.66	-0.84	-0.67		0.51	-0.5	-0.97	-0.86	0.05	-0.09	-0.21	0.62	-0.64	-0.68	0.56	-0.71	-0.86	0.05	-0.5	-0.78	-0.51	0.05	-0.58	-0.7
Retained Earnings	-0.83	-0.29	-0.75	-0.82	-0.95	0.51		-0.5	-0.69	-0.78	0.18	-0.85	-0.57	0.61	-0.84	-0.93	0.55	-0.72	-0.79	0.18	-0.87	-0.8	-0.88	0.13	0.02	-0.81
Accounts Payable	0.49	-0.45	0.38	0.57	0.55	-0.5	-0.5		0.52	0.47	0.31	0.3	0.11	-0.38	0.58	0.54	-0.35	0.8	0.47	0.31	0.42	0.66	0.44	0.34	0.36	0.8
Cash	0.91	-0.03	0.73	0.91	0.81	-0.97	-0.69	0.52		0.93	-0.09	0.3	0.3	-0.67	0.73	0.81	-0.6	0.76	0.92	-0.09	0.68	0.85	0.69	-0.08	0.44	0.79
Cash And Short Term Investments	0.99	0.13	0.77	0.96	0.89	-0.86	-0.78	0.47	0.93		-0.16	0.43	0.64	-0.69	0.87	0.89	-0.61	0.75	1.0	-0.16	0.73	0.82	0.74	-0.14	0.26	0.77
Common Stock Total Equity	-0.16	-0.21	-0.25	-0.23	-0.23	0.05	0.18	0.31	-0.09	-0.16		-0.13	-0.21	0.66	-0.16	-0.2	0.68	0.22	-0.16	1.0	-0.18	-0.27	-0.13	0.99	0.5	0.2
Common Stock Shares Outstanding	0.49	0.58	0.57	0.45	0.73	-0.09	-0.85	0.3	0.3	0.43	-0.13		0.49	-0.33	0.6	0.64	-0.28	0.41	0.44	-0.13	0.61	0.48	0.62	-0.05	-0.24	0.57
Short Term Investments	0.65	0.39	0.46	0.57	0.59	-0.21	-0.57	0.11	0.3	0.64	-0.21	0.49		-0.39	0.73	0.6	-0.34	0.35	0.65	-0.21	0.46	0.33	0.48	-0.21	-0.26	0.33
Non Current Liabilities Total	-0.69	0.06	-0.62	-0.82	-0.76	0.62	0.61	-0.38	-0.67	-0.69	0.66	-0.33	-0.39		-0.72	-0.73	0.99	-0.53	-0.69	0.66	-0.56	-0.86	-0.54	0.61	0.05	-0.55
Other Current Assets	0.9	0.06	0.67	0.92	0.92	-0.64	-0.84	0.58	0.73	0.87	-0.16	0.6	0.73	-0.72		0.92	-0.67	0.83	0.89	-0.16	0.73	0.85	0.74	-0.11	0.12	0.82
Other Stockholder Equity	0.93	0.09	0.79	0.94	0.96	-0.68	-0.93	0.54	0.81	0.89	-0.2	0.64	0.6	-0.73	0.92		-0.66	0.85	0.89	-0.2	0.89	0.91	0.9	-0.18	0.09	0.84
Total Liab	-0.62	0.11	-0.49	-0.76	-0.71	0.56	0.55	-0.35	-0.6	-0.61	0.68	-0.28	-0.34	0.99	-0.67	-0.66		-0.47	-0.62	0.68	-0.51	-0.82	-0.48	0.63	0.1	-0.5
Preferred Stock Total Equity	0.79	-0.24	0.6	0.84	0.79	-0.71	-0.72	0.8	0.76	0.75	0.22	0.41	0.35	-0.53	0.83	0.85	-0.47		0.76	0.22	0.72	0.86	0.74	0.26	0.4	0.94
Total Current Assets	0.99	0.12	0.77	0.96	0.89	-0.86	-0.79	0.47	0.92	1.0	-0.16	0.44	0.65	-0.69	0.89	0.89	-0.62	0.76		-0.16	0.72	0.82	0.73	-0.14	0.26	0.78
Common Stock	-0.16	-0.21	-0.25	-0.23	-0.23	0.05	0.18	0.31	-0.09	-0.16	1.0	-0.13	-0.21	0.66	-0.16	-0.2	0.68	0.22	-0.16		-0.18	-0.27	-0.13	0.99	0.5	0.2
Property Plant And Equipment Net	0.81	0.14	0.6	0.8	0.84	-0.5	-0.87	0.42	0.68	0.73	-0.18	0.61	0.46	-0.56	0.73	0.89	-0.51	0.72	0.72	-0.18		0.77	1.0	-0.14	-0.17	0.73
Current Deferred Revenue	0.85	-0.13	0.73	0.94	0.9	-0.78	-0.8	0.66	0.85	0.82	-0.27	0.48	0.33	-0.86	0.85	0.91	-0.82	0.86	0.82	-0.27	0.77		0.76	-0.22	0.22	0.86
Non Current Assets Total	0.82	0.14	0.61	0.8	0.85	-0.51	-0.88	0.44	0.69	0.74	-0.13	0.62	0.48	-0.54	0.74	0.9	-0.48	0.74	0.73	-0.13	1.0	0.76		-0.1	-0.14	0.75
Non Currrent Assets Other	-0.14	-0.16	-0.24	-0.2	-0.18	0.05	0.13	0.34	-0.08	-0.14	0.99	-0.05	-0.21	0.61	-0.11	-0.18	0.63	0.26	-0.14	0.99	-0.14	-0.22	-0.1		0.47	0.26
Other Assets	0.19	-0.41	0.21	0.19	0.05	-0.58	0.02	0.36	0.44	0.26	0.5	-0.24	-0.26	0.05	0.12	0.09	0.1	0.4	0.26	0.5	-0.17	0.22	-0.14	0.47		0.35
Deferred Long Term Liab	0.8	-0.08	0.61	0.84	0.87	-0.7	-0.81	0.8	0.79	0.77	0.2	0.57	0.33	-0.55	0.82	0.84	-0.5	0.94	0.78	0.2	0.73	0.86	0.75	0.26	0.35

Click cells to compare fundamentals

Solid Biosciences Account Relationship Matchups

Solid Biosciences fundamental ratios Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	171.2M	232.4M	260.3M	164.9M	188.7M	157.6M
Other Current Liab	6.4M	8.1M	14.1M	7.8M	20.0M	21.0M
Total Current Liabilities	24.5M	23.6M	22.5M	14.5M	30.3M	19.6M
Total Stockholder Equity	132.1M	208.2M	211.7M	126.5M	137.2M	89.1M
Net Tangible Assets	80.0M	132.1M	208.2M	211.7M	243.4M	255.6M
Net Debt	(149.6M)	(117.1M)	(126.8M)	(47.8M)	(56.1M)	(58.9M)
Retained Earnings	(404.6M)	(476.8M)	(562.7M)	(658.8M)	(783.5M)	(744.3M)
Accounts Payable	3.3M	4.5M	3.2M	2.0M	4.2M	4.0M
Cash	154.7M	119.1M	155.4M	74.0M	80.2M	91.8M
Cash And Short Term Investments	154.7M	207.8M	213.7M	123.6M	148.9M	133.9M
Common Stock Total Equity	48K	87K	112K	20K	18K	17.1K
Common Stock Shares Outstanding	3.5M	7.1M	8.5M	19.9M	40.8M	42.9M
Short Term Investments	0.0	88.6M	58.3M	49.6M	68.7M	42.1M
Liabilities And Stockholders Equity	171.2M	232.4M	260.3M	164.9M	188.7M	157.6M
Non Current Liabilities Total	14.6M	568K	26.1M	23.9M	21.2M	28.1M
Other Current Assets	4.2M	8.7M	5.9M	6.1M	8.4M	5.1M
Other Stockholder Equity	536.6M	684.9M	774.5M	785.2M	920.6M	471.8M
Total Liab	39.1M	24.2M	48.6M	38.5M	51.4M	42.3M
Total Current Assets	158.9M	222.6M	219.6M	129.7M	157.3M	139.6M
Accumulated Other Comprehensive Income	0.0	(45K)	(68K)	15K	47K	49.4K
Common Stock	48K	87K	112K	20K	40K	38K
Property Plant And Equipment Net	11.7M	7.6M	38.6M	33.2M	29.0M	18.3M
Current Deferred Revenue	8.2M	9.2M	10.4M	8.1M	9.3M	6.7M
Non Current Assets Total	12.3M	9.8M	40.6M	35.2M	31.4M	20.0M
Property Plant And Equipment Gross	11.7M	19.3M	49.6M	45.9M	42.1M	24.3M
Non Current Liabilities Other	5.1M	1.3M	568K	26.1M	30.0M	31.5M
Property Plant Equipment	16.6M	11.7M	6.5M	9.7M	11.1M	9.1M
Net Invested Capital	132.1M	208.2M	211.7M	126.5M	137.2M	132.2M
Net Working Capital	134.4M	199.0M	197.1M	115.2M	127.0M	139.8M
Short Long Term Debt Total	5.2M	2.1M	28.5M	26.3M	24.2M	14.8M
Capital Surpluse	396.3M	536.6M	684.9M	774.5M	890.6M	597.6M
Capital Lease Obligations	5.2M	2.1M	28.5M	26.3M	24.2M	14.8M
Capital Stock	48K	87K	112K	20K	40K	41.4K
Short Term Debt	4.4M	3.0M	5.1M	4.6M	6.0M	4.3M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

HLN	Haleon plc
NVDA	NVIDIA
INTC	Intel

When determining whether Solid Biosciences LLC offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Solid Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Solid Biosciences Llc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Solid Biosciences Llc Stock:

How To Invest In Solid

Details

Is Solid Stock a good investment?

Details

What is Solid Biosciences' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Solid Biosciences LLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in consumer price index.

You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Solid Biosciences. If investors know Solid will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Solid Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(2.79)

Quarterly Revenue Growth

(1.00)

Return On Assets

(0.36)

Return On Equity

(0.68)

The market value of Solid Biosciences LLC is measured differently than its book value, which is the value of Solid that is recorded on the company's balance sheet. Investors also form their own opinion of Solid Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Solid Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Solid Biosciences' market value can be influenced by many factors that don't directly affect Solid Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Solid Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Solid Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Solid Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2025 Macroaxis LLC

Solid Accounts Payable vs Common Stock Total Equity Analysis

Accounts Payable vs Common Stock Total Equity

Accounts Payable vs Common Stock Total Equity Correlation Analysis

Correlation Coefficient

Accounts Payable

Common Stock Total Equity

Solid Biosciences fundamental ratios Correlations

Solid Biosciences Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Solid Biosciences fundamental ratios Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 1.0	Cash And Short Term Investments
Common Stock	+ 1.0	Common Stock Total Equity
Non Current Assets Total	+ 1.0	Property Plant And Equipment Net
Cash And Short Term Investments	+ 0.99	Total Assets
Total Current Assets	+ 0.99	Total Assets
Non Currrent Assets Other	+ 0.99	Common Stock Total Equity

Cash	- 0.97	Net Debt
Retained Earnings	- 0.95	Net Tangible Assets
Other Stockholder Equity	- 0.93	Retained Earnings
Non Current Assets Total	- 0.88	Retained Earnings
Property Plant And Equipment Net	- 0.87	Retained Earnings
Current Deferred Revenue	- 0.86	Non Current Liabilities Total